Neuraptive Therapeutics
PA - Chesterbrook
BiotechnologyFocus: Therapies for nerve repairs
Neuraptive Therapeutics is a life sciences company focused on Therapies for nerve repairs.
Funding Stage
PUBLIC
Total Funding
$11.5M
Open Jobs
0
Pipeline & Clinical Trials
Clinical Trials (1)
NCT05565846NTX-001 to Repair Peripheral Nerve Transection(s)
N/APolyethylene Glycols
Injury of Other Nerves at Wrist and Hand Level of Unspecified Arm, Initial EncounterClinical Trials (1)
NCT03236064Conversion of Seddon III Nerve Injury to Seddon I/II Nerve Injury
Phase 1NTX-001
Peripheral Nerve InjuriesClinical Trials (1)
NCT04572906Safety and Efficacy of NTX-001 Compared to SOC in Acute Single Peripheral Nerve Injuries
Phase 2NTX-001
Facial ParalysisClinical Trials (1)
NCT05293522A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.
Phase 2Phase 3
Clinical Trials (1)
NCT06616025This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2016
Portfolio: 5 clinical trials